Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001

Authors:

Abstract
Background: Neurotrophic tropomyosin receptor kinase (NTRK) gene fusions lead to the transcription of chimeric TRK proteins with overexpressed kinase function; this confers oncogenic potential across several tumor types. Entrectinib is a central nervous system (CNS)-active, potent inhibitor of TRKA/B/C and ROS1. We show integrated efficacy and safety analyses from entrectinib clinical trials.